Studies showed that NK4 could inhibit ovarian cancer cell migration, tumor growth, and peritoneal dissemination in vivo, indicating that NK4 could be an attractive target for therapy in inhibiting HGF/MET pathway [64]. The gene discussed is MET; the disease is ovarian cancer.